No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
Luca Prosperini(Nini Hospital), Giancarlo Di Battista(Associazione Italiana Sclerosi Multipla), Arianna Fornasiero, Diego Centonze(University of Rome Tor Vergata), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Angelo Ghezzi, Simona Pontecorvo(Sapienza University of Rome), Lucia Moiola(Vita-Salute San Raffaele University), Damiano Baroncini, Antonio Bertolotto(Neuroscience Institute), Franco Granella(University of Parma), Paola Sarchielli(University of Perugia), Carlo Avolio(University of Foggia), Massimiliano Mirabella(Università Cattolica del Sacro Cuore), V. Di Tommaso, Marco Puthenparampil(University of Padua), Laura Boffa(University of Rome Tor Vergata), Alice Laroni(Azienda Ospedaliera di Padova), Eugenio Pucci(Ospedale Sant'Anna), Elisabetta Signoriello(ATS Sardegna (Italy)), Luigi Grimaldi(Fondazione Istituto G. Giglio di Cefalù), Alessandra Lugaresi(Istituto delle Scienze Neurologiche di Bologna), Maria Rosaria Rottoli, Gıancarlo Comı(Casa di Cura Columbus), Valeria Barcella, Renato Docimo(Ospedale San Filippo Neri), Marco Salvetti(Istituto Neurologico Mediterraneo), Maria Chiara Buscarinu(Sapienza University of Rome), Giovanna De Luca(University of Udine), Elisabetta Ferraro(IRCCS Ospedale San Raffaele), Matteo Pasca(University of Florence), Paolo Gallo(University of Padua), Maria di Ioia(Ospedale Papa Giovanni XXIII), Luigina Musu(ATS Sardegna (Italy)), Francesco Patti(University of Catania), Valeria Di Francescantonio, Marco Capobianco(Ospedale San Luigi Gonzaga), Gioacchino Tedeschi(University of Campania "Luigi Vanvitelli"), Manuela Matta(Ospedale San Luigi Gonzaga), Roberta Grasso(Ospedale Papa Giovanni XXIII), Assunta Bianco(Università Cattolica del Sacro Cuore), Giacomo Lus(University of Campania "Luigi Vanvitelli"), Antonio Gallo(University of Campania "Luigi Vanvitelli"), Eleonora Cocco(University of Cagliari), Fabio Buttari(Istituto Neurologico Mediterraneo), D. Farina, Luca Mancinelli, Paola Perini(Azienda Ospedale - Università Padova), Pietro Annovazzi(Vita-Salute San Raffaele University)
Cited by 54
Related Papers
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Multiple Sclerosis Severity Score
|Neurology|2005|959
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
|Journal of Neuroinflammation|2016|896
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706